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OBJECTIVE — Thepurposeofthisstudywastoexamineriskfactorsformortalityinpatients
with type 1 diabetes.
RESEARCH DESIGN AND METHODS — Baseline risk factors were measured in the
EURODIAB Prospective Cohort Study with 2,787 type 1 diabetic patients (51% men and 49%
women) recruited from 16 European countries. Mortality data were collected during a 7-year
follow-up.
RESULTS — There was an annual mortality rate of 5 per 1,000 person-years in patients with
type 1 diabetes (mean age at baseline 33 years, range 15–61 years); of the total 2,787 subjects,
102 died. The ﬁnal multivariable model contained age at baseline (standardized hazard ratio
1.78 [95% CI 1.44–2.20]), A1C (1.18 [0.95–1.46]), waist-to-hip ratio (WHR) (1.32 [1.14–
1.52]), pulse pressure (1.33 [1.13–1.58]), and non-HDL cholesterol (1.33 [1.12–1.60]) as risk
factors for all-cause mortality. Macroalbuminuria (2.39 [1.19–4.78]) and peripheral (1.88
[1.06–3.35])andautonomicneuropathy(2.40[1.32–4.36])werethemostimportantriskmarkers
for mortality. Similar risk factors were found for all-cause, non-cardiovascular disease (CVD),
unknown-cause, and CVD mortality.
CONCLUSIONS — Important risk factors for the increased total and non-CVD mortality in
type 1 diabetic patients are age, WHR, pulse pressure, and non-HDL cholesterol. Microvascular
complicationsfrommacroalbuminuriaandperipheralandautonomicneuropathyarestrongrisk
markers for future mortality exceeding the effect of the traditional risk factors.
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T
he presence of type 1 diabetes is as-
sociated with a three- to fourfold in-
creased risk of mortality compared
with that of the general population (1,2).
Itisstillnotclearwhatriskfactorsexplain
thisexcessmortalityrisk.Wehaveshown
that risk factors associated with insulin
resistance, such as triglyceride, waist-to-
hip ratio (WHR), and albuminuria
strongly predict cardiovascular disease
(CVD) in type 1 diabetes (3). Although
CVD is the major cause of death in pa-
tients with type 1 diabetes, it only ac-
counts for approximately half of all
deaths, and it is therefore important to
study the totality of risk and non-CVD
causes of mortality in this young popula-
tion that is particularly vulnerable to pre-
maturedeath.Previousstudieshaveoften
had too few deaths (4) or have not col-
lected key risk factors at baseline (1,2).
The few large cohort studies that have
studied this question have produced in-
consistentﬁndings(4–6),inpartbecause
key common risk factors were not always
included. Therefore, the aim of this study
was to examine risk factors for all-cause
mortality in a large, 7-year prospective co-
hort study of patients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Full details of the de-
sign, methods, and recruitment for the
EURODIAB Prospective Complications
Study (PCS) have been published else-
where (7). This clinic-based prospective
cohort study examined 3,250 type 1 dia-
betic patients between 1989 and 1991.
Participantswereagedbetween15and60
years and were recruited from 31 centers
in 16 European countries. The sampling
frame was all type 1 diabetic patients at-
tending each center at least once in the
past year. Patients were stratiﬁed by age
(three categories), diabetes duration
(three categories), and sex. Ten patients
were then randomly selected from each
stratum (7). Type 1 diabetes was deﬁned
as diabetes diagnosed before the age of 36
years with a continuous need for insulin
within 1 year of diagnosis. Of those in-
vited, 85% participated. Those with du-
ration of diabetes 1 year and pregnant
women were excluded. Ethics committee
approvalwasobtainedateachcenter,and
all subjects provided written informed
consent.
Follow-up
Seven years after baseline examinations,
study participants were invited for reex-
amination. Of the 3,250 subjects at base-
line, 463 individuals could not be
assessed; four centers (n  437) did not
participate in the follow-up examination.
For the remaining 2,787 patients mortal-
ity data were collected during the fol-
low-up (up to 1999). All events were
captured by questionnaire, with addi-
tional supporting information from hos-
pital records and death certiﬁcates. In
addition, a comparison of allocation of
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by two observers with 100% agreement.
Measurements
Allriskfactorsandmicrovascularcompli-
cationsweremeasuredatbaselineaccord-
ing to a standardized protocol (8). Blood
pressurewasrecordedinasittingposition
with a random zero sphygmomanometer
(Hawskley, Lancing, U.K.) and taken as
the mean of two measurements. Hyper-
tension was deﬁned as systolic blood
pressure 140 mmHg or diastolic blood
pressure 90 mmHg and/or the current
useofbloodpressure–loweringdrugs(in-
cluding ACE inhibitors, calcium channel
antagonists,-blockers,[thiazide]diuret-
ics, and -blockers). Pulse pressure was
calculated as the difference between sys-
tolic and diastolic blood pressure.
Retinopathy was assessed by retinal
photographs taken according to the EU-
RODIAB protocol (9). Grading was per-
formed by the Retinopathy Grading
CentreattheHammersmithHospital,Im-
perial College London (London, U.K.).
Retinopathy was classiﬁed as none (level
0),nonproliferative(levels1–3),andpro-
liferative (levels 4 and 5).
Distal neuropathy was diagnosed in
patientswithtwoormoreofthefollowing
fourmeasures(10):thepresenceofoneor
more symptoms, the absence of two or
more reﬂexes of the ankle or knee ten-
dons, a vibration perception threshold
that was abnormal for the patient’s age
(11), and abnormal autonomic function
(loss of heart rate variability with an RR
ratio of 1.04 and/or postural hypoten-
sion with a fall in systolic blood pressure
of 20 mmHg) (12). (For a deﬁnition of
RR,seeTesfayeetal.[10]).“Pure”periph-
eralneuropathywasdeﬁnedasdistalneu-
ropathy without autonomic symptoms or
abnormalautonomicfunctiontestresults.
Autonomic neuropathy was deﬁned in
two ways: 1) according to the above de-
scription (13) or 2) at least two abnormal
tests with a RR ratio of 1.04 and pos-
tural hypotension with a fall in systolic
blood pressure of 30 mmHg.
Laboratory measurements
A single 24-h urine collection was per-
formed to calculate albumin excretion
rate (AER) after excluding proteinuria
due to urinary tract infection using a Ne-
phur dip-stick test for bacteria. Urinary
albumin was measured in a single labora-
tory by an immunoturbidimetric method
(sanoﬁ pasteur, Minneapolis, MN) (14).
AER was categorized as normoalbumin-
uria (20 g/min), microalbuminuria
(between 20 and 200 g/min), and mac-
roalbuminuria (200 g/min). Albu-
minuria was deﬁned as micro- and
macroalbuminuria. A blood sample was
taken for the measurement of plasma lip-
ids (fasting triglycerides, cholesterol, and
HDL cholesterol) and A1C. Triglyceride
(15) and cholesterol (16) concentrations
of plasma and the cholesterol concentra-
tion of HDL (17) were assayed by stan-
dard enzymatic methods (Boehringer
Mannheim, East Sussex, U.K.) using a
COBAS BIO centrifugal analyzer (Roche,
Welwyn Garden City, Herts, U.K.). For
HDL cholesterol, samples with triglycer-
ide concentrations 268 mg/dl were di-
luted with 0.15 mol/l sodium chloride
solution before chemical precipitation.
All analyses were performed centrally.
LDL cholesterol was calculated from
Friedewald’s formula if triglycerides were
4 mmol/l (18). Non-HDL cholesterol
was calculated as HDL cholesterol sub-
tracted from total cholesterol. A1C was
measured centrally by an enzyme immu-
noassay (Dako Ltd., Ely, U.K.) using a
monoclonal antibody raised against A1C
(19).
Statistical analysis
The statistical package Stata 7.0 (Stata
Corporation, College Station, TX) was
usedtoperformallanalyses.P0.05was
considered statistically signiﬁcant. De-
scriptive statistics were calculated. Spear-
man rank correlations were used to test
the cross-sectional relationship between
risk factors. Non-normally distributed
variables were log-transformed. Mortality
rates (per 1,000 person-years) were cal-
culated. Univariate and multivariate Cox
proportional hazards modeling was used
to estimate hazard ratios (HRs) for mor-
tality associated with risk factors. In anal-
yses adjusted for age and duration of
diabetes, mortality was split by non-CVD
causes, CVD causes, unknown causes,
and all causes. A simultaneous and step-
wise approach was used to determine the
most important risk factors. Risk factors
were chosen from the unadjusted Cox
models,selectingoneofeachentityofrisk
factors (e.g., either systolic or diastolic
blood pressure or hypertension), using
P  0.15 as well as evidence from the
literature. Microvascular complications
(retinopathy, albuminuria, and periph-
eralneuropathy)wereenteredinmultiva-
riable models ﬁrst alone and then in
combination with risk factors.
Likelihoodratiotestswereusedtoes-
timate the importance of each risk factor
and to test interaction terms. A full model
with a set of risk factors was compared
with an incomplete model omitting the
risk factor of interest from the previous
model. The P value for the effect of remov-
ing a given risk factor from the model was
obtained by comparing the log likelihoods
from the two models. Standardized hazard
ratios (sHRs) were estimated from these
models by exponentiating the -coefﬁ-
cientmultipliedbytheSD[exp(SD)].
RESULTS— Of the 2,787 (51% men
and 49% women) type 1 diabetic patients
(age at baseline 33 years, range 15–61
years), 102 (4%) died during 7 years of
follow-up (64 men and 38 women;
21,760 person-years of follow-up). The
causes of death were as follows (Table 1):
causes from coronary heart disease
(CHD) (n  24, 24%), other CVD (n  5,
5%), non-CVD (n  38, 37%), and un-
known causes (n  35, 34%). The total
annual mortality rate was 4.7 per 1,000
person-years [95% CI 3.9–5.7] with a
mean age at death of 41 years. Mortality
was greater in men than in women (5.8
per 1,000 person-years [4.5–7.4] vs. 3.6
per 1,000 person-years [2.6–4.9]; P 
0.02). The annual mortality rate for non-
CVD causes was 1.9 per 1,000 person-
years [1.4–2.6], for CVD causes was 1.4
per 1,000 person-years [1.01–2.08], and
Table 1—Causes of death in patients with
type 1 diabetes, EURODIAB PCS
Cause of death n
CHD 24
Other CVD 5
Cancer 9
Sudden death (non-CVD) 2
Respiratory 7
Trafﬁc accident 5
Suicide/murder 5
Diabetes 4
Infection 5
AIDS 1
Unknown 35
Total 102
CHD was deﬁned as myocardial infarction (8), car-
diogenic shock (2), cardiac surgery (2), ischemic
heart disease (7), heart attack (3), and sudden death
(2). Other CVD was deﬁned as cerebrovascular dis-
ease (1), cardiovascular (1), foot gangrene (1), pul-
monary embolus (1), and heart failure (1). Non-
CVD was deﬁned as AIDS (1), suicide/murder (5),
cancer (9), trafﬁc accident (5), sudden death (2),
diabetes (2), diabetes ketoacidosis (1), coma (1), re-
spiratory (7), and infection (5).
Soedamah-Muthu and Associates
DIABETES CARE, VOLUME 31, NUMBER 7, JULY 2008 1361for unknown causes was 1.7 [1.3–2.4]
per 1,000 person-years.
Baseline risk factors were compared
in those patients who were lost to fol-
low-up (n  463) with those included
(n  2,787). Distribution of risk factors
was similar between these groups, except
forahigherprevalenceofsmoking(38vs.
31%), peripheral neuropathy (31 vs.
23%), and use of antihypertensive medi-
cation (15 vs. 9%) in those lost to fol-
low-up compared with those remaining
in the study (data not shown in tables).
Table 2 shows the baseline character-
istics of the study population by overall
mortality status. At baseline, those who
subsequently died of any cause were
older, had diabetes diagnosed at an older
age,andhadalongerdurationofdiabetes
(P  0.0001). Results for modiﬁable risk
factors, including A1C, blood pressure,
lipid proﬁle, central obesity, and physical
activity,werealsoworseatbaseline.Total
insulin dose and daily frequency of insu-
lin injection were less in those who died,
and the burden of other diabetes compli-
cations, both microvascular and macro-
vascular, was greater. Interestingly, BMI
and smoking were not statistically signif-
icantly related to all-cause mortality, even
in univariate analysis.
In Table 3 an overview is given of all
risk factors and microvascular complica-
tions in relation to mortality in patients
with type 1 diabetes. Mortality was split
into non-CVD causes, CVD causes, and
unknown causes, and all analyses were
adjusted for age and duration of diabetes.
Similar risk factors were found for non-
CVD, CVD, unknown-cause, and all-
cause mortality (Table 3), with age, A1C,
systolic and diastolic blood and pulse
pressure, all lipids and lipoproteins,
WHR, hypertension, and microvascular
complications being the most important.
Themaindifferencewasthatmicrovascu-
lar complications (especially macroalbu-
minuria, proliferative retinopathy, and
autonomic neuropathy) seemed stronger
risk factors for CVD mortality than for
non-CVD or unknown-cause mortality.
The multivariable Cox proportional
hazard models for all-cause mortality
wereperformed,respectively,forriskfac-
tors and risk factors plus microvascular
complications. Because of the limited
number of deaths due to CVD mortality,
non-CVD mortality, and unknown-cause
mortality, these models were not split by
cause of death. From multivariable mod-
els, age at baseline (sHR 1.78 [95% CI
1.44–2.20]), WHR (1.32 [1.14–1.52]),
pulse pressure (1.33 [1.13–1.58]), and
non-HDL cholesterol (1.33 [1.12–1.60])
were important risk factors for all-cause
mortality. A1C (1.18 [0.95–1.46]) did
not predict mortality independently any
longer.Microvascularcomplicationswere
studied by comparing models of progres-
sive complexity, ﬁrst one model with
complicationsonlyandthenamodelwith
both complications and risk factors. The
model with all complications, retinopa-
thy, albuminuria (AER), and peripheral
neuropathy, showed that peripheral neu-
ropathy (2.75 [1.60–4.75]) and albu-
minuria (1.71 [1.39–2.10]), but not
retinopathy(1.29[0.69–2.39]),weresig-
niﬁcantly independently related to all-
cause mortality. The model including all
microvascular complications as well as
risk factors (age, A1C, pulse pressure,
WHR, and non-HDL cholesterol showed
that albuminuria (1.58 [1.26–1.98]) and
peripheral neuropathy (1.88 [1.06–
3.35]) exceeded the value of the tradi-
tionalriskfactorsintheirassociationwith
all-cause mortality. These analyses were
Table 2—Baseline characteristics of the EURODIAB PCS cohort by life/death status
Died Survived
n 102 2,685
Age at baseline (years) 41  11 32  10
Age at diabetes diagnosis (years) 20  91 8  8
Duration of diabetes (years) 22  12 14  9
A1C (%)* 8.8  2.2 8.4  1.9
Systolic blood pressure (mmHg) 135  27 121  17
Diastolic blood pressure (mmHg) 78  15 75  11
Pulse pressure (mmHg) 57  21 45  14
Cholesterol (mmol/l) 5.9  1.3 5.3  1.1
LDL cholesterol (mmol/l) 3.8  1.1 3.3  1.0
HDL cholesterol (mmol/l) 1.4  0.5 1.5  0.4
Fasting triglycerides (mmol/l) 1.1 (0.9–1.8) 0.9 (0.7–1.3)
Non-HDL cholesterol (mmol/l) 4.5  1.4 3.8  1.1
Waist-to-hip ratio (men/women) 0.93  0.09/0.84  0.13 0.88  0.08/0.80  0.11
BMI (kg/m
2) (men/women) 24.0  2.9/23.5  3.6 23.6  2.6/23.5  3.0
Insulin dose (units   day
	1   kg
	1) 0.61 (0.49–0.75) 0.67 (0.54–0.81)
AER (g/min) 54.1 (9.8–293.4) 10.8 (6.5–24.0)
Men 64 (63) 1,61 (51)
Current smoking 32 (31) 835 (31)
Low physical activity 55 (54) 1,197 (45)
2–3 insulin injections/day 92 (91) 2,510 (96)
Hypertension 56 (55) 595 (22)
Antihypertensive medication 36 (35) 225 (8)
ACE inhibitors 17 (17) 136 (5)
Calcium channel antagonists 12 (12) 44 (2)
-Blockers 5 (5) 25 (1)
Diuretics 6 (6) 15 (1)
Thiazide diuretics 2 (2) 11 (0.4)
-Blockers 0 (0) 8 (0.3)
Microalbuminuria 24 (26) 549 (21)
Macroalbuminuria 30 (31) 197 (8)
Albuminuria 54 (57) 746 (29)
Nonproliferative retinopathy 24 (38) 771 (35)
Proliferative retinopathy 22 (34) 210 (10)
Retinopathy 46 (72) 981 (45)
Autonomic neuropathy: 1)† 59 (58) 818 (30)
Autonomic neuropathy: 2)† 9 (9) 55 (2)
Peripheral neuropathy 58 (57) 569 (21)
Cardiovascular disease 28 (28) 211 (8)
Data are means  SD, median (interquartile range), or n (%). *Corrected A1C values according to the
DiabetesControlandComplicationsTrialmethod.†Autonomicneuropathywasdeﬁnedintwoways:1)loss
of heart rate variability with an RR ratio of 1.04 and/or postural hypotension with a fall in systolic blood
pressureof20mmHgor2)lossofheartratevariabilitywithanRRratioof1.04andposturalhypotension
with a fall in systolic blood pressure of 30 mmHg.
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cular complications: proliferative reti-
nopathy, macroalbuminuria, and
autonomic neuropathy (deﬁnition 1). A
model with these severe microvascular
complications showed that proliferative
retinopathy (2.46 [1.31–4.60]), auto-
nomic neuropathy (deﬁnition 1) (3.27
[1.83–5.82]), and macroalbuminuria
(3.21 [1.69–6.10]) were all signiﬁcantly
related to all-cause mortality. Adding in
the risk factors showed that autonomic
neuropathy (deﬁnition 1) (2.40 [1.32–
4.36]) and macroalbuminuria (2.34
[1.19–4.78]), but not proliferative reti-
nopathy, were independent risk markers
that exceeded the value of the traditional
risk factors (age, WHR, pulse pressure,
and non-HDL cholesterol). Further anal-
yseswerecarriedoutadjustingforantihy-
pertensive medication, which is a
confounderbyindication.Theseadjusted
analyses yielded similar hazard ratios and
riskfactorsasshownabove.Thosereport-
ing antihypertensive medication were the
high-risk type 1 diabetic patients with a
subsequentlyhigherriskofall-causemor-
tality (as shown in Table 3). Splitting
theseanalysesbytypeofantihypertensive
medication (ACE inhibitors, calcium
channel antagonists, -blockers, [thia-
zide]diuretics,and-blockersaslistedin
Table 2) showed that most reported med-
ications were ACE inhibitors.
The ﬁnal models were expanded with
adjustments for low physical activity and
baseline CVD, but none of the above-
mentioned results were altered, with
sHRs of 2.35 [95% CI 1.29–4.28] and
2.39 [1.18–4.83] for autonomic neurop-
athyandmacroalbuminuria,respectively,
in a full model including proliferative ret-
inopathy, age, A1C, WHR, pulse pres-
sure, non-HDL cholesterol, low physical
activity (1.02 [0.59–1.80]), and baseline
CVD (1.23 [0.58–2.59]). Lastly, an inter-
actionbetweenperipheralandautonomic
neuropathy was tested to examine the
synergistic effect on mortality, but this
yielded nonsigniﬁcant results (P  0.07).
CONCLUSIONS — Important risk
factors for all-cause mortality in patients
with type 1 diabetes are age, WHR, pulse
pressure, and non-HDL cholesterol. Al-
buminuria, especially macroalbuminuria,
and peripheral and autonomic neuropa-
Table 3—Age and duration of diabetes-adjusted analyses between risk factors, microvascular complications, and mortality
sHR (95%CI)
Non-CVD causes CVD mortality Unknown cause All-cause mortality
n 38 29 35 102
Age at baseline (years) 1.94 (1.42–2.66) 1.72 (1.03–2.86) 2.05 (1.29–3.23) 1.87 (1.44–2.45)
Age at diabetes diagnosis (years) 1.70 (1.32–2.19) 1.54 (1.03–2.31) 1.77 (1.23–2.55) 1.65 (1.33–2.04)
Duration of diabetes (years) 1.06 (0.80–1.42) 1.60 (1.03–2.50) 1.16 (0.77–1.75) 1.20 (0.94–1.53)
A1C (%)* 1.25 (0.99–1.58) 1.42 (0.98–2.05) 1.34 (0.96–1.86) 1.30 (1.07–1.58)
Systolic blood pressure (mmHg) 1.48 (1.22–1.80) 1.43 (1.05–1.95) 1.57 (1.20–2.05) 1.46 (1.24–1.73)
Diastolic blood pressure (mmHg) 1.24 (0.99–1.54) 1.34 (0.94–1.89) 1.42 (1.05–1.94) 1.26 (1.05–1.52)
Pulse pressure (mmHg) 1.37 (1.14–1.64) 1.26 (0.93–1.72) 1.35 (1.04–1.76) 1.34 (1.14–1.57)
Cholesterol (mmol/l) 1.38 (1.12–1.71) 1.14 (0.79–1.64) 1.53 (1.15–2.04) 1.31 (1.09–1.58)
LDL cholesterol (mmol/l) 1.28 (0.99–1.66) 1.37 (0.95–1.99) 1.42 (1.01–1.98) 1.32 (1.06–1.63)
HDL cholesterol (mmol/l) 0.74 (0.58–0.96) 0.61 (0.40–0.92) 0.68 (0.46–1.00) 0.70 (0.56–0.87)
Fasting triglycerides (mmol/l)* 1.34 (1.04–1.73) 1.68 (1.16–2.43) 1.45 (1.03–2.02) 1.44 (1.17–1.78)
Non-HDL cholesterol (mmol/l) 1.45 (1.18–1.77) 1.31 (0.94–1.81) 1.60 (1.21–2.11) 1.40 (1.18–1.67)
Waist-to-hip ratio 1.33 (1.12–1.57) 1.35 (1.06–1.73) 1.15 (0.84–1.56) 1.34 (1.17–1.54)
BMI (kg/m
2) 0.90 (0.71–1.14) 1.03 (0.71–1.51) 0.84 (0.59–1.19) 0.93 (0.76–1.14)
Insulin dose (units   day
	1   kg
	1) 0.83 (0.64–1.07) 1.05 (0.69–1.59) 0.83 (0.57–1.21) 0.88 (0.70–1.09)
AER (g/min)* 1.60 (1.34–1.91) 2.22 (1.70–2.91) 1.63 (1.27–2.10) 1.75 (1.51–2.03)
Current smoking 1.34 (0.82–2.19) 0.94 (0.39–2.23) 1.24 (0.60–2.57) 1.23 (0.80–1.88)
Low physical activity 1.14 (0.60–2.15) 0.83 (0.39–1.76) 2.63 (1.25–5.50) 1.36 (0.92–2.02)
2–3 insulin injections/day vs. 1 injection 0.72 (0.29–1.80) 0.39 (0.13–1.16) 0.61 (0.19–2.02) 0.58 (0.29–1.15)
Hypertension 2.22 (1.35–3.63) 3.22 (1.42–7.30) 3.01 (1.46–6.20) 2.44 (1.61–3.72)
Antihypertensive medication 2.09 (0.95–4.62) 3.99 (1.84–8.65) 3.91 (1.91–7.99) 3.15 (2.04–4.85)
Microalbuminuria 1.40 (0.82–2.40) 0.76 (0.29–2.04) 1.10 (0.49–2.44) 1.20 (0.75–1.92)
Macroalbuminuria 3.12 (1.78–5.45) 8.73 (4.03–19.0) 3.31 (1.53–7.17) 4.27 (2.75–6.64)
Albuminuria 2.53 (1.55–4.12) 4.51 (1.94–10.5) 2.21 (1.11–4.42) 2.94 (1.93–4.46)
Non-proliferative retinopathy 0.83 (0.46–1.51) 0.78 (0.28–2.19) 0.84 (0.36–1.97) 0.82 (0.49–1.37)
Proliferative retinopathy 2.77 (1.36–5.63) 7.29 (2.22–23.9) 2.53 (0.94–6.81) 3.58 (1.97–6.51)
Retinopathy 1.73 (0.87–3.42) 6.27 (1.29–30.5) 1.72 (0.64–4.66) 2.23 (1.21–4.12)
Autonomic neuropathy: 1)† 2.81 (1.35–5.83) 3.61 (1.49–8.76) 2.44 (1.20–4.95) 2.83 (1.82–4.38)
Autonomic neuropathy: 2)† 2.73 (0.81–9.24) 3.71 (1.23–11.2) 1.36 (0.32–5.77) 2.45 (1.21–4.96)
Peripheral neuropathy 3.48 (1.72–7.06) 2.24 (1.00–5.04) 2.76 (1.34–5.71) 2.83 (1.84–4.34)
Cardiovascular disease 0.83 (0.29–2.40) 3.20 (1.42–7.20) 3.93 (1.91–8.10) 2.38 (1.50–3.77)
*Log-transformedcorrectedA1CvaluesaccordingtotheDiabetesControlandComplicationsTrialmethod.Coxproportionalhazardsanalyseswereperformed,with
baseline age and diabetes duration adjustments. †Autonomic neuropathy was deﬁned in two ways: 1) loss of heart rate variability with an RR ratio of 1.04 and/or
postural hypotension with a fall in systolic blood pressure of 20 mmHg or 2) loss of heart rate variability with an RR ratio of 1.04 and postural hypotension with
a fall in systolic BP of 30 mmHg.
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cause mortality, exceeding the effect of
the traditional risk factors. Similar risk
factors were found for non-CVD mortal-
ity, CVD mortality, unknown-cause, and
all-cause mortality.
Mortality is high in patients with type
1 diabetes compared with those without
diabetes:intheEURODIABPCS,5deaths
per 1,000 person-years were found. In a
comparable U.K. general population of
the same age-group and no diabetes,
death rates are 
0.2–0.5 per 1,000 per-
son-years (1,2). The all-cause mortality
rates (per 1,000 person-years) of 5.8 in
menand3.6inwomenintheEURODIAB
PCS are comparable with other data.
Theseratesarehigherthanthosefoundin
the Diabetes U.K. cohort study (3.4 per
1,000 person-years in men and 2.6 in
women)(1)butlowerthanthosefoundin
the London cohort of the World Health
Organization (WHO) Multinational
Study of Vascular Disease in Diabetes
(12.6 in men and 14.3 in women) (20).
These differences are consistent with a
long-term declining trend in mortality
rates among people with type 1 diabetes
(21). The most likely explanation for this
trend is improved glycemic therapy and
antihypertensive therapy management
with a resulting decline in morbidity.
The EURODIAB PCS, a clinic-based
study with a large sample size, provides a
useful Europe-wide summary as the same
standardized methods were used in each
center. However, there are some limita-
tions. Referral bias and survival bias are
the main limitations that cannot be en-
tirely avoided, but the extent is reduced
owing to mortality rates comparable with
those of other populations. In the epoch
in which the cohort was recruited, all
those with type 1 diabetes were referred
to a hospital clinic, reducing the extent of
referral bias. Our analyses were focused
on risk factor associations with mortality,
and it is highly unlikely that referral bias
could sufﬁciently alter relationships be-
tween risk factors and mortality. For ex-
ample, it is difﬁcult to postulate a
reasonable hypothesis that would explain
why, for example, a greater WHR in-
creases mortality risk in those referred to
our clinics but reduces mortality risk in
those somehow not referred. This study
was designed primarily as a study of mac-
ro-andmicrovasculardisease,andfactors
more pertinent to conditions such as can-
cer were not collected. Unfortunately, the
number of cigarettes smoked was not col-
lected at baseline, and therefore we could
not calculate smoking pack-years. Smok-
ing, classiﬁed as current smoker, ex-
smoker, or nonsmoker, was not a
signiﬁcant risk factor in our analysis, not
even in univariate analyses. Similarly, for
BMI, there was no signiﬁcant univariate
association with mortality. Although BMI
is still within the normal range, possibly
explaining lack of a relationship, other
reasons for the absence of these associa-
tions remain to be explored. In addition,
those lost-to-follow-up, although a rela-
tively small proportion (14%) of the total
studypopulation,hadamoreatherogenic
proﬁle in terms of neuropathy, use of an-
tihypertensive medication, and smoking
than those included. This could mean
that we have underestimated the number
ofdeathsforbothmenandwomen.How-
ever, the key analysis of the relations be-
tween risk factors and mortality is
unlikely to be affected, as there is no rea-
son to assume that these relations differ
between responders and nonresponders
in the study. Although this is the largest
type 1 diabetic cohort study available, we
hadlimitedpowertofurtheranalyzemul-
tivariate risk factors by speciﬁed causes of
death or to stratify the analyses by sex
because of the limited number of deaths.
Three prospective cohort studies in
type 1 diabetes with published data on
risk factors for all-cause mortality will be
discussedinmoredetail.Rossingetal.(6)
studied 886 patients with type 1 diabetes
from an outpatient diabetic clinic in Den-
mark in 1984, of whom 183 died during
10-yearsoffollow-up.Themainindepen-
dent risk factors for all-cause mortality
were sex, age, height, smoking, social
class, AER, hypertension, serum creati-
nine, and A1C. In the WHO Multina-
tional Study of Vascular Disease in
Diabetes (5), 1,188 (relatively older) pa-
tientswithtype1diabeteswereexamined
during 9 years of follow-up. Proteinuria
was found to be an important indepen-
dentriskfactorforall-causemortality,but
no other risk factors were examined. In
the Epidemiology of Diabetes Complica-
tions (EDC) Study in Pittsburgh (4), 658
patients with type 1 diabetes were exam-
ined during 10 years of follow-up, with
68deathsintotal.Ischemicelectrocardio-
gram, duration of diabetes, previous
CHD, nephropathy, A1C, serum creati-
nine, non-HDL cholesterol, and smoking
were important independent predictors
of mortality. Although the majority of
theseresultsarecomparablewithwhatwe
have found, WHR, lipids, and pulse pres-
sure were not taken into account (5,6).
The baseline age and duration of diabetes
of the different cohort populations dif-
fered, with mean baseline age and dura-
tion of, respectively, 38 and 21 years in
the Danish study (5), 44 and 15 years in
the WHO study (4), and 27 and 19 years
in the EDC study (6) compared with 32
and 14 years in our EURODIAB PCS co-
hort. We conﬁrmed the strong indepen-
dent relationship of albuminuria (or
albumin excretion rate) with all-cause
mortality in patients with type 1 diabetes
(4–6).
Autonomic neuropathy (13) and pe-
ripheral neuropathy (10) were important
independent risk markers of mortality in
theEURODIABPCS.Ameta-analysis(22)
aswellastheEDCstudy(23)showedthat
diabetic autonomic neuropathy was asso-
ciated with a fourfold increase in mortal-
ity. In the EDC study, adjustment for
durationofdiabetesandpresenceofCHD
lowered this risk to 2.1-fold. After further
adjustment for hypertension and ne-
phropathy, the mortality risk associated
with diabetic autonomic neuropathy was
nolongerstatisticallysigniﬁcant(23).We
found HRs of magnitude similar to those
reported in these previous studies, which
inourlargercohortwererobusttoadjust-
ment for other risk factors. Previously it
was shown that peripheral neuropathy
was related to mortality in diabetic pa-
tients but not speciﬁcally to type 1 diabe-
tes (24,25).
In a previous study we had found ret-
inopathy, especially proliferative retinop-
athy,tobeanimportantmarkerforfuture
mortality(26).Theadditionaladjustment
for other microvascular complications re-
duced these ﬁndings to nonsigniﬁcance,
implying that the effects of albuminuria
and neuropathy exceed the effect of
retinopathy.
All of the microvascular complica-
tions were especially strong risk markers
in the multivariable models, exceeding
the effect of traditional risk factors. The
implication of this ﬁnding is that treat-
ment of microvascular complications as
early as possible is highly recommended
to prevent early mortality.
Insummary,thislargestudysupports
evidence for baseline age, WHR, pulse
pressure, and non-HDL cholesterol being
important risk factors for all-cause as well
as non-CVD mortality in patients with
type 1 diabetes. Macroalbuminuria and
peripheralandautonomicneuropathyare
strong risk markers for mortality.
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